Bharat Book Bureau Provides the Trending Market Research Report on “Global Liquid Biopsy Market (by Circulating Biomarker, Product, Application, End User, Clinical Application, Cancer Types, Sample Type, Regional & Country Wise Analysis), Initiatives, Funding, Major Deals, 35 Company Profiles and Recent Developments - Forecast to 2027 ”under Healthcare Category. The report offers a collection of superior market research, market analysis, competitive intelligence and Market reports.

The global liquid biopsy market is expected to reach nearly US$ 8.2 Billion by 2027. Liquid biopsy is a non-invasive technology that detects molecular biomarkers using liquid sample without the need for costly or invasive procedures. Liquid biopsy aids in planning the required treatment and also check for treatment effectiveness as well as repeated occurrence of tumor during and after the course of cancer treatment. The abilities of liquid biopsy like, easy and minimal invasiveness, early cancer diagnosis & detection, characterization of new lesions, drug & therapeutic target identifications for cancer treatment are some advantages of liquid biopsies, which improve the safety and efficiency of cancer therapy for patients.
The advantages of liquid biopsy over solid tumor biopsy, rising prevalence of cancer, increasing preference for non-invasive procedures, growing public and private funding to support research activities in the field of liquid biopsy and favorable government initiatives, are some of the factors expected to propel the growth of liquid biopsy market in the coming years. Some of the key factors inhibiting the growth of liquid biopsy market includes, clinical utility challenges, lack of sensitivity and specificity of liquid biopsy tests and unclear reimbursement & regulation scenario.
Recent Developments
• In June 2020, NeoGenomics, Inc. announced the launch of three liquid biopsy tests for advanced non-small cell lung cancer, all solid tumor types (pan-cancer), and certain breast cancer cases.
• In June 2020, Guardant Health presented new data demonstrating that its LUNAR-2 liquid biopsy is a highly sensitive test that can detect early-stage colorectal cancer.
• In January 2020, Personal Genome Diagnostics Inc. partnered with Eisai Co., Ltd. to develop a comprehensive liquid biopsy biomarker discovery solution for oncology

Request a free sample copy Liquid Biopsy Market Report @
https://www.bharatbook.com/marketreports/sample/reports/2164994

Data Sources
Employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by iGATE Research dedicated team of qualified professionals with deep industry experience and expertise.
Research Methodologies
Primary Research Methodologies: Questionnaires, Surveys, Interviews with Individuals, Small Groups, Telephonic Interview, etc.
Secondary Research Methodologies: Printable and Non-printable sources, Newspaper, Magazine and Journal Content, Government and NGO Statistics, white Papers, Information on the Web, Information from Agencies Such as Industry Bodies, Companies Annual Report, Government Agencies, Libraries and Local Councils and a large number of Paid Databases.

Browse our full report with Table of Content :
https://www.bharatbook.com/marketreports/global-liquid-biopsy-market-by-circulating-biomarker-product-application-end-user-clinical-application-cancer-type/2164994

About Bharat Book Bureau:
Bharat Book is Your One-Stop-Shop with an exhaustive coverage of 4,80,000 reports and insights that includes latest Market Study, Market Trends & Analysis, Forecasts Customized Intelligence, Newsletters and Online Databases. Overall a comprehensive coverage of major industries with a further segmentation of 100+ subsectors.

Contact us at:
Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Email: [email protected]
Website: www.bharatbook.com